Clinical Research Directory

Inclusion Criteria: * Age 18 years or older. * Ability to understand the study requirements and provide written informed consent. * Histologically confirmed relapsed or refractory aggressive mature B-cell non-Hodgkin lymphoma. * Failure of at least one prior line of systemic anticancer therapy. * Documented CD19 expression on tumor cells by immunohistochemistry and/or flow cytometry/immunophenotyping of current disease. * Considered eligible for CD19-directed CAR T-cell therapy by the treating multidisciplinary team, with no absolute contraindication to CAR T-cell therapy at the time of enrollment. * At least one measurable FDG-avid lesion according to Lugano 2014 criteria. * Baseline PET/CT performed within 28 days before enrollment. * ECOG performance status 0-2. * Life expectancy of at least 12 weeks. * No severe uncontrolled comorbid condition that would preclude protocol therapy. * Women of childbearing potential must have a negative pregnancy test before study treatment and agree to use highly effective contraception; male participants must agree to follow protocol-specified contraceptive requirements. Exclusion Criteria: * Prior treatment with a CD20×CD3 bispecific antibody. * Absence of confirmed CD19 expression on tumor cells. * No indication for, or any contraindication to, CD19-directed CAR T-cell therapy. * ECOG performance status ≥3. * Uncontrolled bacterial, viral, fungal, or opportunistic infection, including sepsis. * Active hepatitis B or C infection, HIV infection, or syphilis. * Concurrent active malignancy not in remission. * Active autoimmune disease requiring systemic immunosuppressive therapy. * Ongoing systemic corticosteroid therapy at a dose equivalent to \>10 mg/day of prednisone, except physiologic replacement therapy or protocol-required premedication. * Clinically significant uncontrolled cardiovascular, pulmonary, neurologic, or psychiatric disease. * Grade ≥2 peripheral sensory or motor neuropathy according to CTCAE. * Known hypersensitivity to any study drug or its components. * Pregnancy or breastfeeding. * Any other condition that, in the investigator's judgment, would place the participant at unacceptable risk or interfere with study treatment or required study procedures.